Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Apr 1:2019:5180895.
doi: 10.1155/2019/5180895. eCollection 2019.

Colorectal Peritoneal Metastases: A Systematic Review of Current and Emerging Trends in Clinical and Translational Research

Affiliations
Review

Colorectal Peritoneal Metastases: A Systematic Review of Current and Emerging Trends in Clinical and Translational Research

Foteini Stefania Koumpa et al. Gastroenterol Res Pract. .

Abstract

Colorectal peritoneal metastases (CPM) are associated with abbreviated survival and significantly impaired quality of life. In patients with CPM, radical multimodality treatment consisting of cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) has demonstrated oncological superiority over systemic chemotherapy alone. In highly selected patients undergoing CRS + HIPEC, overall survival of over 60% has been reported in some series. These are patients in whom the disease burden is limited and where the diagnosis is made at an early stage in the disease course. Early diagnosis and a deeper understanding of the biological mechanisms that regulate CPM are critical to refining patient selection for radical treatment, personalising therapeutic approaches, enhancing prognostication, and ultimately improving long-term survivorship. In the present study, we outline three broad themes which represent critical future research targets in CPM: (1) enhanced radiological strategies for early detection and staging; (2) identification and validation of translational biomarkers for diagnostic, prognostic, and therapeutic deployment; and (3) development of optimized approaches for surgical cytoreduction as well as more precise strategies for intraperitoneal drug selection and delivery. Herein, we provide a contemporary narrative review of the state of the art in these three areas. A systematic review in accordance with PRISMA guidelines was undertaken on all English language studies published between 2007 and 2017. In vitro and animal model studies were deemed eligible for inclusion in the sections pertaining to biomarkers and therapeutic optimisation, as these areas of research currently remain in the early stages of development. Acquired data were then divided into hierarchical thematic categories (imaging modalities, translational biomarkers (diagnostic/prognostic/therapeutic), and delivery techniques) and subcategories. An interactive sunburst figure is provided for intuitive interrogation of the CPM research landscape.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Modified preferred reporting items for systematic reviews and meta-analysis flow diagram outlining study selection strategy.
Figure 2
Figure 2
Sunburst figure for visual interpretation of the CPM research landscape. Figure generated using the D3 JavaScript library. A static version of the figure is presented here, and a link to the interactive figure for more targeted interrogation of the available data for given categories and subcategories is provided as supplementary material.

References

    1. Chu D. Z., Lang N. P., Thompson C., Osteen P. K., Westbrook K. C. Peritioneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors. Cancer. 1989;63(2):364–367. doi: 10.1002/1097-0142(19890115)63:2<364::aid-cncr2820630228>3.0.co;2-v. - DOI - PubMed
    1. Sadeghi B., Arvieux C., Glehen O., et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer. 2000;88(2):358–363. doi: 10.1002/(SICI)1097-0142(20000115)88:2<358::AID-CNCR16>3.0.CO;2-O. - DOI - PubMed
    1. Jayne D. G., Fook S., Loi C., Seow-Choen F. Peritoneal carcinomatosis from colorectal cancer. The British Journal of Surgery. 2002;89(12):1545–1550. doi: 10.1046/j.1365-2168.2002.02274.x. - DOI - PubMed
    1. Mohamed F., Cecil T., Moran B., Sugarbaker P. A new standard of care for the management of peritoneal surface malignancy. Current Oncology. 2011;18(2):e84–e96. - PMC - PubMed
    1. Elias D., Lefevre J. H., Chevalier J., et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. Journal of Clinical Oncology. 2009;27(5):681–685. doi: 10.1200/JCO.2008.19.7160. - DOI - PubMed

LinkOut - more resources